

# Shedding of Tumor Necrosis Factor Receptor 1 Induced by Protein A Decreases Tumor Necrosis Factor Alpha Availability and Inflammation during Systemic *Staphylococcus aureus* Infection

Constanza Gai,<sup>a</sup> Cintia Gonzalez,<sup>a</sup> Camila Ledo,<sup>b</sup> Ailin Garofalo,<sup>b</sup> María Silvia Di Genaro,<sup>c</sup> Daniel O. Sordelli,<sup>a</sup> Marisa I. Gomez<sup>a</sup>

Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM), Consejo Nacional de Investigaciones Científicas y Tecnológicas, Universidad de Buenos Aires, Buenos Aires, Argentina<sup>a</sup>; Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina<sup>b</sup>; Instituto Multidisciplinario de Investigaciones Biológicas (IMIBIO), Consejo Nacional de Investigaciones Científicas y Tecnológicas, Universidad de San Luis, San Luis, Argentina<sup>c</sup>

***Staphylococcus aureus* infections are an important public health concern due to their increasing incidence and high rates of mortality. The success of *S. aureus* as a pathogen is highly related to its enormous capacity to evade the host immune response. The critical role of tumor necrosis factor alpha (TNF- $\alpha$ ) in the initial host defense against systemic staphylococcal infection has been demonstrated in experimental models and may partially explain the lack of significant benefits observed in clinical trials attempting to neutralize this cytokine in septic patients. *S. aureus* protein A plays a key role in regulating inflammation through its ability to bind and signal through the TNF- $\alpha$  receptor 1 (TNFR1). In this study, we demonstrate that *S. aureus*, via protein A-mediated signaling, induces early shedding of TNFR1, which precedes the secretion of TNF- $\alpha$  *in vitro* and *in vivo*. The results obtained using a protein A-deficient mutant and *tnfr1*<sup>-/-</sup> mice strongly suggest that the increased levels of soluble TNFR1 present during experimental *S. aureus* infection may neutralize circulating TNF- $\alpha$  and impair the host inflammatory response. Early shedding of TNFR1 induced by protein A may constitute a novel mechanism by which *S. aureus* subverts the host immune response.**

*Staphylococcus aureus* is a major hospital- and community-acquired pathogen (1–3). The incidence of severe sepsis and septic shock is steadily increasing, and worldwide mortality ranges from 30% to 50% (4, 5). The increasing worldwide prevalence of antibiotic-resistant strains, which renders staphylococcal infections very difficult to treat and eradicate, is a serious public health concern (6–8).

*S. aureus* infections are characterized by a profound inflammatory response, which contributes significantly to pathogenesis but is also required for bacterial clearance (9). Among the proinflammatory cytokines induced, tumor necrosis factor alpha (TNF- $\alpha$ ) has been shown to be crucial for the eradication of bacteria in several experimental models (10, 11). TNF- $\alpha$ -induced signaling is modulated by the availability of its cognate receptor, TNF receptor 1 (TNFR1), at the cell surface. The abundance of TNFR1 is positively controlled in response to several stimuli by mobilization from intracellular compartments and can be negatively regulated by shedding of the extracellular domain from the surface (12–14). TNFR1 is cleaved from the cell surface by ADAM17 (15–17), a mechanism that decreases the amount of receptor available to respond to the ligand and terminates TNF- $\alpha$  signaling, thus modulating inflammation (18, 19).

Among the many factors that determine the pathogenicity of *S. aureus*, protein A, a surface protein, acts as an exceptionally complex virulence factor, contributing to the success of *S. aureus* as a pathogen by interfering with immune clearance and also by inducing inflammation. In addition to its roles in immunoglobulin G binding (20, 21), platelet activation (22), and B cell activation (23, 24), protein A plays a key role in stimulating inflammation through its ability to bind and signal through TNFR1 (25). TNFR1 signaling triggered by protein A initiates the production of interleukin 8 (IL-8) and the recruitment of neutrophils to the site of

infection (26). Protein A induces other proinflammatory cytokines and chemokines, such as type I interferon (IFN) and CXCL10, in airway epithelial cells and macrophages, which also contribute to neutrophil recruitment and bacterial clearance (27–29).

We have shown previously that *S. aureus* protein A activates ADAM17 in airway epithelial cells (30). Considering that this protease is a key molecule in the regulation of TNF- $\alpha$ -TNFR1 signaling, and given the central role of this cascade in the immune responses orchestrated by macrophages, this study was aimed at investigating the role of *S. aureus* protein A in the activation of ADAM17 in macrophages, the induction of soluble TNFR1 (sTNFR1) *in vivo*, and the regulation of TNF- $\alpha$  availability during systemic staphylococcal infection.

## MATERIALS AND METHODS

**Recombinant proteins and bacterial strains.** Full-length protein A cloned from *S. aureus* strain Newman, the IgG binding domains (EC region), the carboxyl-terminal polymorphic region (X), and IgG binding domain D and its corresponding L17A mutant were expressed as glutathione S-transferase (GST) fusion proteins in *Escherichia coli* BL21 and were purified as described previously (29). The recombinant proteins were dialyzed against phosphate-buffered saline (PBS) and were used at a

Received 15 May 2013 Returned for modification 14 June 2013

Accepted 19 August 2013

Published ahead of print 3 September 2013

Editor: B. A. McCormick

Address correspondence to Marisa I. Gomez, marisagomez@gmail.com.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/IAI.00593-13

concentration of 2.5  $\mu\text{M}$  for *in vitro* stimulation. Potentially remaining traces of lipopolysaccharide (LPS) were removed using Detoxi-Gel endotoxin-removing gel and columns (Pierce, Holmdel, NJ). The proteins were proved to be free of LPS by testing of their stimulatory capacities in the presence or absence of polymyxin B.

*S. aureus* strain Newman and the *spa*-deficient isogenic mutant (deficient in the *spa* gene, which encodes protein A) were grown in Trypticase soy broth (Britania, Buenos Aires, Argentina) and were suspended in RPMI 1640 medium (Life Technologies, Grand Island, NY) at a concentration of  $1 \times 10^9$  CFU/ml. A clinical isolate of *Escherichia coli* (isolate 515; generously provided by D. Centron, IMPaM, UBA-CONICET, Buenos Aires, Argentina) and *Pseudomonas aeruginosa* PAO-1 (31) were grown in Luria-Bertani agar (Britania, Buenos Aires, Argentina) and were suspended in RPMI 1640 medium (Life Technologies, Grand Island, NY) at a concentration of  $1 \times 10^9$  CFU/ml. *Lactococcus lactis* MG1363 carrying the pKS80 vector containing full-length *spa* or an empty-vector control (provided by Tim Foster, Trinity College, Dublin, Ireland) was grown in M17 medium supplemented with 0.5% glucose and 5  $\mu\text{g}/\text{ml}$  erythromycin at 30°C without agitation (29, 32, 33). Cells were harvested by centrifugation at 10,000 rpm for 10 min, and the pellet was suspended in RPMI 1640 medium (Life Technologies, Grand Island, NY) at a concentration of  $5 \times 10^8$  CFU/ml.

**Cell culture.** RAW 264.7 cells (a mouse macrophage cell line) and THP-1 cells (a human monocytic/macrophage cell line) were cultured in RPMI 1640 medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum, 0.11 mg/ml pyruvate (Sigma-Aldrich, St. Louis, MO), 0.29 mg/ml GlutaMAX (Life Technologies, Grand Island, NY), and  $1 \times$  nonessential amino acids (Life Technologies, Grand Island, NY). RAW 264.7 cells cultured to confluence were weaned from serum 24 h before exposure to stimuli. THP-1 cells were used at  $10^6/\text{ml}$ . Where indicated, biochemical inhibitors were added 30 min prior to stimulation and during stimulation.

**Detection of TNF- $\alpha$  and soluble TNFR1.** TNF- $\alpha$  and soluble TNFR1 were quantified in culture supernatants by enzyme-linked immunosorbent assays (ELISA) using DuoSet antibody pairs (R&D Systems, Minneapolis, MN).

**Flow cytometry.** After stimulation, cells were washed three times with PBS and were stained with an antibody against ADAM17 (Santa Cruz Biotechnology, Dallas, TX) followed by an Alexa Fluor 488-conjugated secondary antibody. The cells were analyzed in a Partec PAS III flow cytometer, and the data were analyzed with WinMDI software.

**In vivo studies.** Six-week-old BALB/c mice obtained from the Department of Microbiology, School of Medicine, University of Buenos Aires animal facility were used unless otherwise indicated. C57BL/6 *tnfrp55*<sup>-/-</sup> (*tnfr1*<sup>-/-</sup>) mice were obtained from the Max von Pettenkofer Institute, Munich, Germany. Breeding colonies were established at the animal facility of the National University of San Luis (San Luis, Argentina). Mice were inoculated intraperitoneally with 200  $\mu\text{l}$  of either recombinant protein A (at a dose of 0.125 nmol/g, based on a mouse model of LPS-induced endotoxemia [34] and our previous studies [29]), wild-type *S. aureus*, a protein A-deficient mutant ( $2 \times 10^8$  CFU/ml), *E. coli* 515 ( $2 \times 10^8$  CFU/ml), or PBS as control. Blood samples were obtained by puncture of the retro-orbital plexus at different times after inoculation. Serum was stored at -80°C for subsequent TNF- $\alpha$  and sTNFR1 quantification. Peritoneal cells were harvested using 8 ml of cold RPMI 1640 medium supplemented with 2% fetal bovine serum. The cells were then washed by centrifugation and were used for RNA extraction or surface antigen staining and flow cytometry analysis.

For neutrophil detection, peritoneal-cell suspensions were stained with phycoerythrin (PE)-labeled anti-CD45 and fluorescein isothiocyanate (FITC)-labeled anti-Ly6G (BD Pharmingen, San Jose, CA) as described previously (26). Negative-control samples were incubated with irrelevant isotype-matched antibodies. Cells were gated based on their forward-scatter (FSC)/side-scatter (SSC) profiles and were analyzed for the double expression of CD45 and Ly6G with WinMDI software.

Animal studies were approved by the Institutional Committee for the Care and Use of Laboratory Animals (CICUAL) of the University of Buenos Aires.

**Western blotting.** Cells were lysed using 60 mM *n*-octyl- $\beta$ -D-glucopyranoside in TBS (0.1 M Tris-HCl and 0.15 M NaCl [pH 7.8]) containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), 1 mM sodium orthovanadate, and 100 mM sodium fluoride. Proteins were separated on 8% bis-acrylamide gels, transferred to a nitrocellulose membrane, and blocked with 5% milk in TBST (50 mM Tris [pH 7.5], 150 mM NaCl, and 0.05% Tween) for 1 h at room temperature. Immunodetection was performed using antibodies against phosphorylated extracellular signal-regulated kinases 1 and 2 (phospho-ERK1/2) (Santa Cruz Biotechnology, Dallas, TX) or actin (Sigma-Aldrich, St. Louis, MO), followed by secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Dallas, TX). Images were analyzed with ImageJ software.


**Real-time PCR.** RNA was isolated using TRIzol reagent (Life Technologies, Grand Island, NY). cDNA was made from 1  $\mu\text{g}$  of RNA using ImProm-II reverse transcriptase (Promega, Fitchburg, WI). For quantitative real-time PCR, amplification was performed in an Applied Biosystems thermal cycler. The following primers were used for amplification: for mouse TNF- $\alpha$ , 5'-ATG AGC ACA GAA AGC ATG ATC-3' and 5'-TAC AGG CTT GTC ACT CGA ATT-3'; for mouse ADAM17, 5'-ATG TGA GCA GTT TCC CGA ACG-3' and 5'-ATC AAG CTT CTC AAG TCG CGG-3'; and for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5'-GAA GGT GGT GAA GCA GGC AT-3' and 5'-TCG AAG GTG GAA GAG TGG GA-3'. GAPDH was used as a control for standardization.

**Statistics.** Data from samples with normal distribution were analyzed using the Student *t* test. Data from samples that did not follow normal distribution were analyzed with the nonparametric Mann-Whitney test or the Wilcoxon test from GraphPad Prism software, version 4.0. A *P* value lower than 0.05 was considered statistically significant.


## RESULTS

### *S. aureus* protein A induces TNFR1 shedding in macrophages.

We investigated the ability of protein A to activate ADAM17 in macrophages and to induce TNFR1 shedding. Significant increases in the concentrations of soluble TNFR1 (sTNFR1) were observed in culture supernatants from macrophages stimulated with protein A (Fig. 1A and B). We have demonstrated previously that the interaction of protein A with the epidermal growth factor receptor (EGFR) mediates ADAM17 activation and TNFR1 shedding in airway epithelial cells (30). Thus, we next investigated whether the amino-terminal portion of protein A, known to interact with the EGFR, was involved in sTNFR1 production in macrophages. TNFR1 shedding was observed when macrophages were stimulated with recombinant GST-tagged proteins corresponding to the amino-terminal region containing the IgG binding domains (EC fragment) of protein A, as opposed to stimulation with the carboxyl-terminal region (X fragment) (Fig. 1A). The interaction of leucine 17, located in the conserved amino-terminal domain of protein A, is necessary for the recognition of protein A by the EGFR and the subsequent phosphorylation of ADAM17 on threonine by ERK1/2 in airway epithelial cells (30). Therefore, we determined the role of protein A-EGFR-mediated signaling in the shedding of TNFR1 from macrophages by using a mutated (L17A) form of protein A. Cells stimulated with the L17A mutant showed reduced levels of sTNFR1 (Fig. 1C). In agreement with these findings, ERK1/2 phosphorylation was observed starting at 15 min after stimulation (Fig. 1D), and chemical inhibition of ERK1/2 significantly reduced the levels of sTNFR1 induced in response to protein A (Fig. 1E). In agreement with our previous findings in airway epithelial cells (28), ADAM17 was abundantly



**FIG 1** Activation of ADAM17 and TNFR1 shedding in response to protein A. (A through C) RAW 264.7 cells (A and C) and THP-1 cells (B) were stimulated with the amino-terminal portion of protein A (EC), the polymorphic region of protein A (X), full-length protein A (SpA), IgG binding domain D (D), its corresponding L17A mutant (L17A), GST (control), or medium alone (unstimulated [U]), and the induction of sTNFR1 was determined by ELISA. (D) RAW 264.7 cells were stimulated with the amino-terminal portion of protein A (EC) or with medium alone (U), and phospho-ERK1/2 was detected at different time points by immunoblotting. Bars show the densitometric quantification of phospho-ERK relative to actin, which was used to normalize the protein charge. a.u., arbitrary units. (E) RAW 264.7 cells were stimulated with protein A in the absence (control [C]) or presence (PD) of the MEK1/2 inhibitor PD98058 (10  $\mu$ M), and the induction of sTNFR1 was determined 30 min later by ELISA. (F) The expression of ADAM17 on the surfaces of unstimulated RAW 264.7 cells was determined by flow cytometry. Open histogram, cells stained with an antibody to ADAM17; shaded histogram, cells stained with normal goat serum as a control. (G) RAW 264.7 cells were stimulated with recombinant protein A for the times indicated or with medium alone (U) and were stained for surface expression of ADAM17. MFI, mean fluorescence intensity. (H) RAW 264.7 cells were stimulated for the times indicated with protein A, GST (control), or medium alone (U), and the transcription of ADAM17 was quantified by real-time PCR and was standardized to GAPDH expression. Data in panels A through C, E, G, and H are means and standard deviations of cumulative data from three independent experiments ( $n$ , 3 for each experiment). Asterisks indicate significant differences (\*,  $P$  < 0.05; \*\*,  $P$  < 0.01; \*\*\*,  $P$  < 0.001) by Student's  $t$  test.




**FIG 2** TNF- $\alpha$  production and shedding of TNFR1 in response to protein A. RAW 264.7 cells were stimulated for the times indicated with wild-type *S. aureus* or a protein A-deficient mutant (*spa* mutant) (A and B), *L. lactis* expressing protein A (*L. lactis* SpA) or *L. lactis* containing a control vector (*L. lactis* CV) (C and D), *E. coli* (E), *Pseudomonas aeruginosa* (PAO-1) (F), or medium alone (unstimulated [U]), and the induction of TNF- $\alpha$  (A and C) and sTNFR1 (B, D, E, and F) was determined by ELISA. Data are means and standard deviations of cumulative data from three independent experiments ( $n$ , 3 for each experiment). Asterisks indicate significant differences (\*,  $P$  < 0.05; \*\*,  $P$  < 0.01) by Student's  $t$  test.

expressed at the surfaces of macrophages (Fig. 1F); no further amounts of the enzyme were mobilized in response to protein A (Fig. 1G); and no transcriptional regulation was observed at the times studied (Fig. 1H).

**Release of sTNFR1 precedes TNF- $\alpha$  production in *S. aureus*-stimulated macrophages.** The kinetics of TNF- $\alpha$  production and TNFR1 shedding in response to whole live *S. aureus* was investigated in macrophages. *S. aureus* induced TNF- $\alpha$  production starting at 1 h after stimulation, and significantly larger amounts of this cytokine were detected 1 h later (Fig. 2A). Although the response was significantly diminished, cells stimulated with a protein A-deficient isogenic mutant still produced TNF- $\alpha$  (Fig. 2A). Interestingly, shedding of TNFR1 occurred as soon as 30 min after the exposure of macrophages to *S. aureus* and was highly dependent on protein A expression (Fig. 2B). The role of protein A in the induction of both TNF- $\alpha$  and sTNFR1 was confirmed by stimulating macrophages with *Lactococcus lactis* expressing protein A (*L. lactis* SpA). As was found with *S. aureus*, sTNFR1 released in response to *L. lactis* SpA was detected before TNF- $\alpha$  production (Fig. 2C and D). In contrast, early shedding of TNFR1 was not observed when macrophages were stimulated with an equal dose of the Gram-negative bacterium *Escherichia coli* or *Pseudomonas aeruginosa* (Fig. 2E and F).


***S. aureus* protein A induces shedding of TNFR1 *in vivo*.** To demonstrate the biological relevance of the *in vitro* findings, we



**FIG 3** Induction of sTNFR1 in response to protein A. Groups of mice were inoculated intraperitoneally with recombinant protein A (filled circles) or PBS (control) (open circles), and at different time points, sTNFR1 (A, C, E, and G) and TNF- $\alpha$  (B, D, F, and H) levels in serum were quantified by ELISA. Each pair of dots represents an individual mouse at the time points indicated. Asterisks indicate significant differences (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ) by the Wilcoxon matched-pairs test.

determined whether protein A could induce TNFR1 shedding *in vivo*. Mice were inoculated intraperitoneally with protein A, and the amounts of sTNFR1 and TNF- $\alpha$  in serum were quantified over time. A significant increase in the level of circulating sTNFR1 was observed as soon as 30 min after inoculation (Fig. 3A), and this response was sustained at least up to 4 h (Fig. 3C, E, and G). TNF- $\alpha$  levels in serum increased 1 h after inoculation (median, 716 pg/ml) (Fig. 3D) and peaked 1 h later (median, 1,800 pg/ml) (Fig. 3F). These results show that in agreement with the kinetics seen *in vitro*, after *in vivo* inoculation of protein A, significant levels of sTNFR1 were found in the circulation before TNF- $\alpha$  was detected.

**Soluble TNFR1 released in response to protein A neutralizes TNF- $\alpha$  during systemic *S. aureus* infection.** In order to evaluate the kinetics of TNFR1 shedding and TNF- $\alpha$  induction during staphylococcal infection, groups of mice were inoculated intraperitoneally with *S. aureus* or the *spa*-deficient strain, and the levels of sTNFR1 and TNF- $\alpha$  in serum were analyzed over time. A significant increase in the amount of circulating sTNFR1 was observed starting at 1 h after challenge with wild-type *S. aureus* (Fig. 4A). By 2 h after inoculation with *S. aureus*, the amount of sTNFR1 in the circulation had increased ~2,000 pg over basal levels, whereas no differences were observed for mice inoculated with the *spa*-deficient mutant (Fig. 4A). Conversely, a significant




**FIG 4** Shedding of TNFR1 during *S. aureus* infection. Groups of mice were inoculated intraperitoneally with wild-type *S. aureus* (light shaded boxes), a protein A-deficient mutant (*spa*-deficient mutant) (dark shaded boxes), or PBS (control) (open boxes). At different time points, sTNFR1 (A) and TNF- $\alpha$  (B) levels in serum were quantified by ELISA. Each box represents an individual group of mice, and horizontal lines show the median value for each group. Asterisks indicate significant differences (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ) by the Mann-Whitney test for nonparametric data. (A) The change in sTNFR1 levels ( $\Delta$ sTNFR1) was calculated for each individual mouse at the indicated time points as the sTNFR1 level after inoculation minus the sTNFR1 level prior to inoculation. (B) The change in TNF- $\alpha$  levels ( $\Delta$ TNF- $\alpha$ ) was calculated for each individual mouse at the indicated time points as the TNF- $\alpha$  level after inoculation minus the TNF- $\alpha$  level prior to inoculation. Basal levels of sTNFR1 and TNF- $\alpha$  prior to inoculation (median values) were 1,500 pg/ml and 45 pg/ml, respectively.


increase in the levels of circulating TNF- $\alpha$  was observed for mice inoculated with the *spa*-deficient mutant 4 h after inoculation, whereas this cytokine could not be detected in sera from mice inoculated with wild-type *S. aureus* (Fig. 4B).

We confirmed that *S. aureus* infection was indeed able to induce TNF- $\alpha$  production *in vivo* by quantifying TNF- $\alpha$  transcription in peritoneal infiltrates. Significant increases in TNF- $\alpha$  mRNA levels were observed in mice infected with either *S. aureus* or the *spa*-deficient mutant by 2 and 4 h after inoculation (Fig. 5).

Based on the data obtained using the wild-type strain and the *spa*-deficient mutant, we hypothesized that the absence of detect-




**FIG 5** TNF- $\alpha$  expression during *S. aureus* infection. Mice were inoculated intraperitoneally with wild-type *S. aureus*, a protein A-deficient mutant (*spa*-deficient mutant), or PBS (control), and TNF- $\alpha$  expression by peritoneal cells at the times indicated was quantified by real-time PCR and was normalized to GAPDH expression. Each bar represents the mean and standard deviation for 3 to 5 mice. Asterisks indicate significant differences (\*,  $P < 0.05$ ) by Student's *t* test. n.s., not significant.



**FIG 6** TNF- $\alpha$  induction during systemic *S. aureus* infection in TNFR1-deficient mice. Groups of C57BL/6 (wild-type) and *tnfr1*<sup>-/-</sup> mice were inoculated intraperitoneally with wild-type *S. aureus* (A and B) or the *spa*-deficient mutant (A), and 4 h later, TNF- $\alpha$  levels in serum were quantified by ELISA. Each symbol represents an individual mouse, and horizontal lines show the median value for each group. Asterisks indicate significant differences (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ) by the Mann-Whitney test for nonparametric data.

able TNF- $\alpha$  during infection with *S. aureus* may be due to its neutralization by the sTNFR1 induced in response to protein A. In agreement with this hypothesis, we observed that mice inoculated with *E. coli* did not present an increase in circulating sTNFR1 levels and showed increased levels of TNF- $\alpha$  in serum at 2 and 4 h after challenge (data not shown). These results agree with previous observations for mice challenged with LPS, where TNF- $\alpha$  was found in the circulation at 2 h postinoculation, while sTNFR1 was detected only at 24 h (35). To further demonstrate the neutralization of TNF- $\alpha$  by sTNFR1 *in vivo*, we compared the levels of TNF- $\alpha$  in serum from TNFR1-deficient (*tnfr1*<sup>-/-</sup>) and wild-type (C57BL/6) mice under basal conditions and after *S. aureus* inoculation. In agreement with the results obtained for BALB/c mice, C57BL/6 mice challenged with the *spa*-deficient mutant had levels of TNF- $\alpha$  in the circulation significantly higher than those in mice challenged with wild-type *S. aureus* (Fig. 6A). Basal levels of circulating TNF- $\alpha$  were similar in wild-type and *tnfr1*<sup>-/-</sup> mice (Fig. 6B). Although the levels of circulating TNF- $\alpha$  increased in both groups after *S. aureus* inoculation, the amounts of TNF- $\alpha$  detected in the sera of *tnfr1*<sup>-/-</sup> mice were double those found in wild-type mice (Fig. 6B). However, statistical significance was not achieved, probably due to the lack of positive regulation of TNF- $\alpha$  via TNFR1 signaling in *tnfr1*<sup>-/-</sup> mice. This hypothesis is supported by the fact that the concentrations of TNF- $\alpha$  in sera from *tnfr1*<sup>-/-</sup> mice challenged with *S. aureus* were indeed lower than the amounts found in wild-type mice challenged with the *spa*-deficient mutant (Fig. 6A and B).

**Early shedding of TNFR1 decreases inflammation during *S. aureus* infection.** We then determined the consequences of the early shedding of TNFR1 for the inflammatory status of mice systemically infected with *S. aureus*. We observed that 24 h after inoculation, the levels of circulating TNF- $\alpha$  were significantly lower in mice inoculated with wild-type *S. aureus* than in those inoculated with the *spa*-deficient mutant (Fig. 7A). The levels of



**FIG 7** Inflammatory response induced during systemic *S. aureus* infection. Groups of mice were inoculated intraperitoneally with wild-type *S. aureus* (filled circles) or a protein A-deficient mutant (*spa*-deficient mutant) (shaded circles). Open circles indicate values for mice inoculated with PBS as a control. Twenty-four hours later, the levels of TNF- $\alpha$  (A), IL-1 $\beta$  (B), and IL-6 (C) in serum were quantified by ELISA, and the percentage of neutrophils in the peritoneum was determined by flow cytometry (D). Each symbol represents an individual mouse, and horizontal lines show the median value for each group. Asterisks indicate significant differences (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ) by the Mann-Whitney test for nonparametric data.

IL-1 $\beta$ , a proinflammatory cytokine regulated by TNF- $\alpha$ , were also significantly lower in mice inoculated with wild-type *S. aureus* than in mice inoculated with the *spa*-deficient mutant (Fig. 7B). The levels of IL-6, a cytokine that has dual pro- and anti-inflammatory functions, were not affected (Fig. 7C). Moreover, the percentage of neutrophils recruited to the infection site 24 h after inoculation was significantly lower in mice inoculated with wild-type *S. aureus* than in mice inoculated with the *spa*-deficient mutant (Fig. 7D).

## DISCUSSION

Despite the critical role of TNF- $\alpha$  in the eradication of bacteria, excessively high levels of this cytokine may lead to tissue damage, organ failure, and death, a frequent scenario for septic patients (36). For this reason, TNF- $\alpha$  has been neutralized in many clinical trials in an attempt to prevent the undesirable effects of this cytokine (37). The different approaches considered have included the use of monoclonal antibodies to TNF- $\alpha$  (38) and the TNF receptor fused to the Fc portion of IgG (39). The outcomes of these trials, however, failed to show any significant beneficial effect on the evolution of septic patients, indicating not only that other mediators of inflammation are involved in sepsis but also that, clearly, certain levels of TNF- $\alpha$  are required for bacterial eradication (10, 40). TNF- $\alpha$  supports host antibacterial defenses through several mechanisms, including potentiation of the killing of bacteria by neutrophils and upregulation of vascular and adhesion molecules, which are necessary for neutrophil recruitment (40). In this regard, treatment of inflammatory diseases, such as lupus or rheumatoid arthritis, with neutralizing antibodies to TNF- $\alpha$  has led to increased risks of infectious diseases (41, 42), including infections caused by *S. aureus* (43).


One of the major strategies through which *S. aureus* causes infection in humans is evasion of the host immune response, for which it has an enormous capacity (21, 44). In the present study, we demonstrated that protein A induces the early shedding of

TNFR1 *in vivo* during systemic *S. aureus* infection. Receptor cleavage precedes the release of TNF- $\alpha$  both *in vitro* and *in vivo*. The results obtained in experiments using a protein A-deficient mutant and *tnfr1*<sup>-/-</sup> mice strongly suggest that the increased levels of circulating sTNFR1 induced by *S. aureus* may neutralize circulating TNF- $\alpha$  and interfere with the host inflammatory response in the initial phase of infection.

TNF- $\alpha$  signaling is finely regulated by the availability of TNFR1 at the cell surface. The cleavage of the receptor ectodomain by ADAM17 culminates TNFR1 signaling and produces a soluble receptor that potentially neutralizes circulating TNF- $\alpha$ . The importance of downregulating TNF- $\alpha$  signaling has been demonstrated in patients with TNFR-associated periodic syndrome (TRAPS). These patients exhibit a mutation in TNFR1 that impairs its cleavage from the cell surface, reducing the levels of sTNFR1 in serum to half of those found in normal individuals, which leads to a chronic inflammatory condition characterized by fever and cutaneous and articular inflammation (45). Whereas downregulation of TNF- $\alpha$  signaling is important, excessive liberation of sTNFR1 may lead to an imbalance of the immune response. In this regard, the presence of high levels of circulating sTNFR1 and other soluble molecules, such as sTNFR2 and IL-1 receptor antagonist (IL-1Ra), is a marker of poor prognosis for septic patients. It has been proposed that these molecules may contribute to an anti-inflammatory state by blocking the action of TNF- $\alpha$  and IL-1 $\beta$ , thus impairing bacterial clearance (46). To date, no experimental studies aimed at investigating the release of these decoy molecules during *S. aureus* infection *in vivo* have been performed.

Activation of ADAM17 and shedding of TNFR1 by immune cells have been reported in response to septic stimuli *in vitro* (13, 47) and in animal models of LPS-induced endotoxemia (19, 35). Shedding of TNFR1, which occurs between 6 and 24 h after LPS inoculation, was critical for the neutralization of TNF- $\alpha$  signaling and the arrest of inflammation (19). The results presented in this study suggest that *S. aureus* may exploit this physiological downregulatory mechanism to its own benefit and that the cleavage of TNFR1 at an early time point during infection may serve to neutralize the action of TNF- $\alpha$ . Whereas TNF- $\alpha$  induction depends on the recognition of several *S. aureus* antigens, such as teichoic acids, peptidoglycan, lipoproteins, and protein A (9), we demonstrated that early shedding of TNFR1 is highly dependent on protein A expression, underscoring the role of this virulence factor in the evasion of the immune response. The ability of protein A to activate ADAM17 rapidly seems crucial in this process, since TNFR1 is already available at the cell surface and thus can be cleaved before TNF- $\alpha$  is induced. Whereas blockade of TNF- $\alpha$  using a neutralizing antibody given in combination with antibiotics 3 days after infection reduces staphylococcal arthritis and sepsis (48), early studies with experimental models using recombinant TNF- $\alpha$  have demonstrated that this cytokine contributes to the initial host defense against *S. aureus* (49). Moreover, it has also been reported that inhibition of endogenous TNF- $\alpha$  increases mortality during *S. aureus* infection (11, 48), demonstrating the important role of this cytokine during the initial host response.

Interestingly, *P. aeruginosa* and *E. coli* did not induce early shedding of TNFR1, indicating that receptor cleavage is not a general immune evasion mechanism used by bacteria and highlighting the importance of distinguishing between Gram-positive and Gram-negative bacteria during the study of ADAM17 and TNF-



**FIG 8** Protein A induces pro- and anti-inflammatory signaling cascades. (Left) Protein A interacts with TNF- $\alpha$  receptor 1 (TNFR1) in airway epithelial and immune cells. Activation of TNFR1 causes the induction of IL-8 by airway epithelial cells and of TNF- $\alpha$  and IL-1 $\beta$  by immune cells, with consequent recruitment of neutrophils to the infection site. (Right) The interaction of protein A with the epidermal growth factor receptor (EGFR) mediates ADAM17 activation and TNFR1 shedding in airway epithelial and immune cells. The release of soluble TNFR1 in response to protein A neutralizes the action of TNF- $\alpha$  and decreases the amount of receptor that is available to respond to this cytokine, thus impairing the downstream inflammatory cascade.

$\alpha$ /TNFR1 signaling modulation in sepsis. In this regard, it is noteworthy that the majority of clinical trials attempting to modulate TNF- $\alpha$ -driven immune responses have not taken into account during data analysis the potential differences in results according to the etiology of sepsis. Moreover, the most commonly used experimental model of sepsis is the murine cecal ligation and puncture model, in which peritonitis is induced by a mixture of anaerobic and facultatively anaerobic Gram-negative and Gram-positive bacteria (50–52). Whereas this model might be very useful for understanding the pathophysiology of sepsis with a peritoneal focus, studies investigating the immune responses induced by single pathogens are also needed. Indeed, it has been demonstrated that ADAM17 deficiency leads to protection against lethal shock by LPS (53, 54), whereas iRhom2-deficient mice, in which ADAM17 cannot be activated, failed to control the replication of the Gram-positive bacterium *Listeria monocytogenes* (55). Moreover, several experimental studies reveal that TNF- $\alpha$ -neutralizing therapy may adversely affect survival in Gram-positive models of peritonitis, cerebritis, and bacteremia (40).

The results presented here also seem to indicate that a given virulence factor may have differential roles in pathogenesis according to the type of infection. Protein A can act either as a proinflammatory or as an anti-inflammatory molecule. In the context of pulmonary infection, the inflammatory response induced by protein A via TNFR1 initiates IL-8 signaling and neutrophil recruitment to the lungs (Fig. 8), with deleterious consequences for pulmonary function (26). The early action of TNF- $\alpha$  in the lung is very limited, because airway epithelial cells do not produce significant levels of this cytokine, and prior recruitment of immune cells is required for TNF- $\alpha$  levels to peak. In contrast, in a systemic infection, immune cells are readily available to produce TNF- $\alpha$ , a potent contributor to bacterial clearance. In this scenario, the early shedding of TNFR1 induced by protein A may

constitute a novel strategy by which *S. aureus* subverts the host immune response by neutralizing the action of TNF- $\alpha$  (Fig. 8). The study of signaling cascades that are critical for the initiation of the host immune response and that are altered by bacterial components may allow the identification of novel alternative targets for *S. aureus* infection therapy.

## ACKNOWLEDGMENTS

This work was supported by grants from the Agencia Nacional de Promoción de la Ciencia y la Tecnología, Argentina (PICT 07-01012, PICT 10-2152, and PICT11-2263), and the Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, Buenos Aires, Argentina (UBACyT 20020090200180), to M.G.

We thank Daniela Ureta for technical assistance with flow cytometry.

## REFERENCES

- Rasmussen RV, Fowler VG, Jr, Skov R, Bruun NE. 2011. Future challenges and treatment of *Staphylococcus aureus* bacteremia with emphasis on MRSA. *Future Microbiol.* 6:43–56.
- van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. 2012. Predictors of mortality in *Staphylococcus aureus* bacteremia. *Clin. Microbiol. Rev.* 25:362–386.
- Lam SW, Bauer SR, Neuner EA. 2012. Predictors of septic shock in patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *Int. J. Infect. Dis.* 16:e453–e456.
- Kotsaki A, Giamarellos-Bourboulis EJ. 2012. Emerging drugs for the treatment of sepsis. *Expert Opin. Emerg. Drugs* 17:379–391.
- Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. 2007. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA* 298:1763–1771.
- Lowy FD. 2007. Secrets of a superbug. *Nat. Med.* 13:1418–1420.
- Boucher H, Miller LG, Razonable RR. 2010. Serious infections caused by methicillin-resistant *Staphylococcus aureus*. *Clin. Infect. Dis.* 51(Suppl 2): S183–S197.
- Ippolito G, Leone S, Lauria FN, Nicastrì E, Wenzel RP. 2010. Methicillin-resistant *Staphylococcus aureus*: the superbug. *Int. J. Infect. Dis.* 14(Suppl 4):S7–S11.
- Fournier B, Philpott DJ. 2005. Recognition of *Staphylococcus aureus* by the innate immune system. *Clin. Microbiol. Rev.* 18:521–540.
- Abraham E. 1999. Why immunomodulatory therapies have not worked in sepsis. *Intensive Care Med.* 25:556–566.
- Nakane A, Okamoto M, Asano M, Kohanawa M, Minagawa T. 1995. Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in *Staphylococcus aureus* infection in mice. *Infect. Immun.* 63:1165–1172.
- Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, Lassmann H, Kollias G. 2004. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. *J. Exp. Med.* 200:367–376.
- Bell JH, Herrera AH, Li Y, Walcheck B. 2007. Role of ADAM17 in the ectodomain shedding of TNF- $\alpha$  and its receptors by neutrophils and macrophages. *J. Leukoc. Biol.* 82:173–176.
- Scheller J, Chalaris A, Garbers C, Rose-John S. 2011. ADAM17: a molecular switch to control inflammation and tissue regeneration. *Trends Immunol.* 32:380–387.
- Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA. 2000. Functional analysis of the domain structure of tumor necrosis factor- $\alpha$  converting enzyme. *J. Biol. Chem.* 275:14608–14614.
- Gooz M. 2010. ADAM-17: the enzyme that does it all. *Crit. Rev. Biochem. Mol. Biol.* 45:146–169.
- Levine SJ. 2004. Mechanisms of soluble cytokine receptor generation. *J. Immunol.* 173:5343–5348.
- Westlund KN, Zhang L, Ma F, Oz HS. 2012. Chronic inflammation and pain in a tumor necrosis factor receptor (TNFR) (p55/p75<sup>-/-</sup>) dual deficient murine model. *Transl. Res.* 160:84–94.
- Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, Nahmias Y, Goldwasser Y, Kitagawa Y, Tilles AW, Tompkins RG, Parekkadan B, Yarmush ML. 2010. Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1. *Mol. Ther.* 18:1857–1864.
- Moks T, Abrahmsen L, Nilsson B, Hellman U, Sjoquist J, Uhlen M. 1986. Staphylococcal protein A consists of five IgG-binding domains. *Eur. J. Biochem.* 156:637–643.
- Foster TJ. 2005. Immune evasion by staphylococci. *Nat. Rev. Microbiol.* 3:948–958.
- Hartleib J, Kohler N, Dickinson RB, Chhatwal GS, Sixma JJ, Hartford OM, Foster TJ, Peters G, Kehrel BE, Herrmann M. 2000. Protein A is the von Willebrand factor binding protein on *Staphylococcus aureus*. *Blood* 96:2149–2156.
- Sasso EH, Silverman GJ, Mannik M. 1989. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. *J. Immunol.* 142: 2778–2783.
- Silverman GJ, Goodyear CS. 2006. Confounding B-cell defences: lessons from a staphylococcal superantigen. *Nat. Rev. Immunol.* 6:465–475.
- Gómez MI, O'Seaghda M, Magargée M, Foster TJ, Prince AS. 2006. *Staphylococcus aureus* protein A activates TNFR1 signaling through conserved IgG binding domains. *J. Biol. Chem.* 281:20190–20196.
- Gómez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, Cheung A, Prince A. 2004. *Staphylococcus aureus* protein A induces airway epithelial inflammatory responses by activating TNFR1. *Nat. Med.* 10:842–848.
- Martin FJ, Gómez MI, Wetzel DM, Memmi G, O'Seaghda M, Soong G, Schindler C, Prince A. 2009. *Staphylococcus aureus* activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. *J. Clin. Invest.* 119:1931–1939.
- Gómez MI, Sokol SH, Muir AB, Soong G, Bastien J, Prince AS. 2005. Bacterial induction of TNF- $\alpha$  converting enzyme expression and IL-6 receptor alpha shedding regulates airway inflammatory signaling. *J. Immunol.* 175:1930–1936.
- Garofalo A, Giai C, Lattar S, Gardella N, Mollerach M, Kahl BC, Becker K, Prince AS, Sordelli DO, Gómez MI. 2012. The length of the *Staphylococcus aureus* protein A polymorphic region regulates inflammation: impact on acute and chronic infection. *J. Infect. Dis.* 206:81–90.
- Gómez MI, Seaghda MO, Prince AS. 2007. *Staphylococcus aureus* protein A activates TACE through EGFR-dependent signaling. *EMBO J.* 26: 701–709.
- Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warren P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrook-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* 406:959–964.
- O'Brien L, Kerrigan SW, Kaw G, Hogan M, Penadés J, Litt D, Fitzgerald DJ, Foster TJ, Cox D. 2002. Multiple mechanisms for the activation of human platelet aggregation by *Staphylococcus aureus*: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. *Mol. Microbiol.* 44:1033–1044.
- O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ. 2002. *Staphylococcus aureus* clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. *Cell. Microbiol.* 4:759–770.
- Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. 2007. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. *Eur. J. Pharmacol.* 571:231–239.
- Bobrowski WF, McDuffie JE, Sobocinski G, Chupka J, Olle E, Bowman A, Albassam M. 2005. Comparative methods for multiplex analysis of cytokine protein expression in plasma of lipopolysaccharide-treated mice. *Cytokine* 32:194–198.
- Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. *N. Engl. J. Med.* 348:138–150.
- Marshall JC. 2003. Such stuff as dreams are made on: mediator-directed therapy in sepsis. *Nat. Rev. Drug Discov.* 2:391–405.
- Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. 1998. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. *Lancet* 351:929–933.
- Fisher CJ, Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. 1996. Treatment of septic shock

- with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. *N. Engl. J. Med.* 334:1697–1702.
40. Lorente JA, Marshall JC. 2005. Neutralization of tumor necrosis factor in preclinical models of sepsis. *Shock* 24(Suppl 1):107–119.
  41. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. 2006. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. *Health Technol. Assess.* 10(42):iii-iv, xi-xiii, 1–229.
  42. Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP. 2006. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. *Clin. Exp. Rheumatol.* 24:587–593.
  43. Marques M, Rodrigues S, Mariz E, Pinto J, Videira T, Brito J, Reis C, Simoes-Ventura F, Magro F. 2010. Severe gram positive bacterial infection in an ulcerative colitis patient treated with Infliximab. *J. Crohns Colitis* 4:110–113.
  44. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. 2012. Recurrent infections and immune evasion strategies of *Staphylococcus aureus*. *Curr. Opin. Microbiol.* 15:92–99.
  45. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumara-jeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane KA, Molloy MG, Ranki A, Powell RJ, Hitman GA, O'Shea JJ, Kastner DL. 1999. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell* 97:133–144.
  46. de Pablo R, Monserrat J, Reyes E, Diaz-Martin D, Rodriguez Zapata M, Carballo F, de la Hera A, Prieto A, Alvarez-Mon M. 2011. Mortality in patients with septic shock correlates with anti-inflammatory but not pro-inflammatory immunomodulatory molecules. *J. Intensive Care Med.* 26:125–132.
  47. Robertshaw HJ, Brennan FM. 2005. Release of tumour necrosis factor alpha (TNF $\alpha$ ) by TNF $\alpha$  cleaving enzyme (TACE) in response to septic stimuli in vitro. *Br. J. Anaesth.* 94:222–228.
  48. Fei Y, Wang W, Kwiecinski J, Josefsson E, Pullerits R, Jonsson IM, Magnusson M, Jin T. 2011. The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice. *J. Infect. Dis.* 204:348–357.
  49. Vaudaux P, Grau GE, Huggler E, Schumacher-Perdreau F, Fiedler F, Waldvogel FA, Lew DP. 1992. Contribution of tumor necrosis factor to host defense against staphylococci in a guinea pig model of foreign body infections. *J. Infect. Dis.* 166:58–64.
  50. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW, III, Bland KI, Chaudry IH. 2005. Cecal ligation and puncture. *Shock* 24(Suppl 1):52–57.
  51. Dejager L, Pinheiro I, Dejonckheere E, Libert C. 2011. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? *Trends Microbiol.* 19:198–208.
  52. Secher T, Vasseur V, Poisson DM, Mitchell JA, Cunha FQ, Alves-Filho JC, Ryffel B. 2009. Crucial role of TNF receptors 1 and 2 in the control of polymicrobial sepsis. *J. Immunol.* 182:7855–7864.
  53. Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y, Blobel CP. 2007. TNF- $\alpha$ -converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. *J. Immunol.* 179:2686–2689.
  54. Long C, Wang Y, Herrera AH, Horiuchi K, Walcheck B. 2010. In vivo role of leukocyte ADAM17 in the inflammatory and host responses during *E. coli*-mediated peritonitis. *J. Leukoc. Biol.* 87:1097–1101.
  55. McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, Berger T, Murthy A, Duncan G, Xu HC, Lang KS, Haussinger D, Wakeham A, Itie-Youten A, Khokha R, Ohashi PS, Blobel CP, Mak TW. 2012. iRhomb2 regulation of TACE controls TNF-mediated protection against *Listeria* and responses to LPS. *Science* 335:229–232.